Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Pimecrolimus is an immunosuppressant drug of the calcineurin inhibitor class used in the treatment of atopic dermatitis (eczema).
Read the full article on WikipediaAtopic dermatitis Clinical criteria: Population criteria: Patient must be at least 3 months of age. The condition must be on the patient's face; OR The condition must be on the patient's eyelid, AND Patient must have 1 or more of the following contraindications to topical corticosteroids: (i) perioral dermatitis; (ii) periorbital dermatitis; (iii) rosacea; (iv) epidermal atrophy; (v) dermal atrophy; (vi) allergy to topical corticosteroids; (vii) cataracts; (viii) glaucoma; (ix) raised intraocular pressure, AND Patient must not receive more than two 15 g packs of PBS-subsidised pimecrolimus per 6-month period.
Working under the parallel aged-care framework? Aged-care equivalent →